Lipe & Dalton Pfizer Inc Transaction History

Lipe & Dalton

$189 Million
Q4 2024

A detailed history of Lipe & Dalton transactions in Pfizer Inc stock. As of the latest transaction made, Lipe & Dalton holds 2,659 shares of PFE stock, worth $67,964. This represents 0.04% of its overall portfolio holdings.

Number of Shares

2,659

Previous 2,259 17.71%

Holding current value

$67,964

Previous $65,000 9.23%

% of portfolio

0.04%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 03, 2025	BUY	$24.8 - $30.19 $9,920 - $12,076	400 Added 17.71%	2,659 $71,000
Q2 2024 Aug 02, 2024	SELL	$25.26 - $29.6 $12,630 - $14,800	-500 Reduced 18.12%	2,259 $63,000
Q1 2022 Apr 26, 2022	SELL	$45.75 - $56.69 $3,660 - $4,535	-80 Reduced 2.82%	2,759 $143,000
Q1 2021 Apr 30, 2021	SELL	$33.49 - $37.77 $33 - $37	-1 Reduced 0.04%	2,839 $103,000
Q4 2020 Jan 29, 2021	SELL	$33.47 - $42.56 $7,664 - $9,746	-229 Reduced 7.46%	2,840 $105,000
Q1 2020 May 01, 2020	SELL	$27.03 - $38.62 $12,163 - $17,379	-450 Reduced 12.79%	3,069 $100,000
Q2 2019 Jul 24, 2019	SELL	$36.98 - $41.52 $36,980 - $41,520	-1,000 Reduced 22.13%	3,519 $152,000
Q4 2018 Feb 08, 2019	BUY	$38.47 - $43.86 $38,470 - $43,860	1,000 Added 28.42%	4,519 $197,000
Q2 2018 Aug 06, 2018	BUY	$32.98 - $35.16 $4,946 - $5,273	150 Added 4.45%	3,519 $128,000
Q1 2018 May 04, 2018	BUY	$31.91 - $37.02 $2,552 - $2,961	80 Added 2.43%	3,369 $120,000
Q4 2017 Feb 13, 2018	SELL	$33.26 - $35.29 $44,468 - $47,182	-1,337 Reduced 28.9%	3,289 $119,000
Q2 2017 Aug 08, 2017	BUY	N/A	4,626	4,626 $155,000

Others Institutions Holding PFE

# of Institutions

3,346

Shares Held

3.69B

Call Options Held

106M

Put Options Held

123M

View Full List

About PFIZER INC

Ticker PFE
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 5,612,349,952
Market Cap $143B
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...

More about PFE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lipe & Dalton, based on Form 13F filings with the SEC.

News

Stay updated on Lipe & Dalton with notifications on news.

Account